These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6803540)

  • 41. Binding of thrombin-activated human factor VIII to platelets.
    Soberano ME; Clarke D; Zucker MB
    Br J Haematol; 1986 Nov; 64(3):571-85. PubMed ID: 3098274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Von Willebrand disease with an increased ristocetin-induced platelet aggregation and a qualitative abnormality of the factor VIII protein.
    Takahashi H; Sakuragawa N; Shibata A
    Am J Hematol; 1980; 8(3):299-308. PubMed ID: 6774612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abnormality of glycoprotein Ib in two cases of "pseudo"-von Willebrand's disease.
    Bryckaert MC; Pietu G; Ruan C; Tobelem G; Girma JP; Meyer D; Larrieu MJ; Caen JP
    J Lab Clin Med; 1985 Oct; 106(4):393-400. PubMed ID: 2931492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The agglutination of human platelets by bovine factor VIII: R.
    Kirby EP
    J Lab Clin Med; 1982 Dec; 100(6):963-76. PubMed ID: 6183384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    Weiss HJ; Rogers J; Brand H
    J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor.
    Allain JP; Cooper HA; Wagner RH; Brinkhous KM
    J Lab Clin Med; 1975 Feb; 85(2):318-28. PubMed ID: 234499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subcellular platelet factor VIII antigen and von Willebrand factor.
    Nachman RL; Jaffe EA
    J Exp Med; 1975 May; 141(5):1101-13. PubMed ID: 1168691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents.
    Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
    Thromb Res; 1999 Sep; 95(6):315-23. PubMed ID: 10527409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of carbohydrate modifications of factor VIII/von Willebrand factor on binding to platelets.
    Goudemand J; Mazurier C; Samor B; Bouquelet S; Montreuil J; Goudemand M
    Thromb Haemost; 1985 Jun; 53(3):390-5. PubMed ID: 2864750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Defective ristocetin and bovine factor VIII-induced platelet aggregation in normal rats.
    de Gaetano G; Donati MB; Reyers-Degli Innocenti I; Roncaglioni MC
    Experientia; 1975 Apr; 31(4):500-2. PubMed ID: 1120536
    [No Abstract]   [Full Text] [Related]  

  • 51. Heterogeneity of human factor VIII. II. Characterization of forms of factor VIII binding to platelets in the presence of ristocetin.
    Doucet-de Bruïne MH; Sixma JJ; Over J; Beeser-Visser NH
    J Lab Clin Med; 1978 Jul; 92(1):96-107. PubMed ID: 659967
    [No Abstract]   [Full Text] [Related]  

  • 52. The role of platelet von Willebrand factor in the binding of factor VIII to activated platelets.
    Suzuki H; Shima M; Kamisue S; Nakai H; Nogami K; Shibata M; Morichika S; Tanaka I; Giddings JC; Yoshioka A
    Thromb Res; 1998 Jun; 90(5):207-14. PubMed ID: 9694242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Function and ultrastructure of platelets of neonates: enhanced ristocetin aggregation of neonatal platelets.
    Ts'ao CH; Green D; Schultz K
    Br J Haematol; 1976 Feb; 32(2):225-33. PubMed ID: 1247495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proceedings: Interaction of ristocetin (R), von Willebrand factor (vWF), factor VIII clotting activity (VIIIc) and platelets.
    Zucker MB; McPherson J; Kim SJ; Macdonald VE; Taylor D; Johnson AJ; Barlow GH
    Thromb Diath Haemorrh; 1975 Nov; 34(2):582. PubMed ID: 1081748
    [No Abstract]   [Full Text] [Related]  

  • 55. The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility.
    Coller BS
    J Clin Invest; 1978 May; 61(5):1168-75. PubMed ID: 307006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
    Miller JL; Kupinski JM; Castella A; Ruggeri ZM
    J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma aggregating factor (bovine) for human platelets: a marker for study of antihemophilic and von Willebrand Factors.
    Griggs TR; Cooper HA; Webster WP; Wagner RH; Brinkhous KM
    Proc Natl Acad Sci U S A; 1973 Oct; 70(10):2814-8. PubMed ID: 4542779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monoclonal antibody to human platelet glycoprotein I. II. Effects on human platelet function.
    Ruan C; Tobelem G; McMichael AJ; Drouet L; Legrand Y; Degos L; Kieffer N; Lee H; Caen JP
    Br J Haematol; 1981 Dec; 49(4):511-9. PubMed ID: 6797459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Surface labelling as a tool to determine structure-function relationships of platelet plasma membrane glycoproteins.
    Phillips DR
    Thromb Haemost; 1980 Feb; 42(5):1638-51. PubMed ID: 6768157
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.